SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (AMEX:INO), a late stage developer of a novel tumor ablation therapy and enabler of DNA vaccines by using electroporation to deliver drugs and nucleic acids, announced today that Dr. Remco De Bree will present a paper, titled “Chemo-electroporation in the head and neck for otherwise untreatable patients,” at the 5th International Symposium on Advances in Head & Neck Cancer taking place February 1 - 3 in Marburg, Germany. Dr. De Bree has been a participating physician in a European pre-marketing clinical study for head and neck cancer using Inovio’s Selective Electrochemical Tumor Ablation (SECTA) therapy. The paper, co-authored by De Bree R, Tijing BM, van Dongen GAMS, and Leemans CR, notes that the therapy “has the potential to become a valuable addition to the treatment options for patients with head and neck tumors.”
